Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Aged ≥60 Years Treated with a 10-Day Decitabine Schedule Versus Intensive Chemotherapy in the AML21 Study (NCT02172872)Adriano Venditti, Francesco Buccisano, Anna Candoni et al.|Blood|2023Cited by 1